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Work accomplished in Year 2
In Year 2, all outstanding year 1 tasks (genomic profiling and samples collection) were completed or very near completion and both year 2 tasks were in progress. Data integration of miRNA, DNA methylation, gene expression and mutation data identified promising candidate oncogenes and tumor suppressor genes, including EYA4, SIRPA, YEATS4, and ELF3 (Year 2 task 1). Manuscripts detailing the biological roles of these genes have been published or are in preparation and are appended. Analysis of miRNA sequencing data identified a panel of 18 miRNAs altered in >90% of tumor samples relative to matched non-malignant tissue. These miRNAs were validated in external cohorts and in pre validation samples to confirm their expression in blood and determine their concordance between tissue and blood samples (Year 1 task 6 & Year 2 task 2)
In addition, we performed a validation study on one of Dr. Hanash's blood biomarkers -Pro-surfactant protein B (pro-SFTPB) using blood samples from the Pan-Canadian Early Lung Cancer Detection Study. When adjusted for age, sex, body mass index, personal history of cancer, family history of lung cancer, forced expiratory volume in 1 second percent predicted, average number of cigarettes smoked per day, and smoking duration, plasma level of pro-SFTPB was found to be an important independent predictor of lung cancer (J Clin Oncol 31 (36) :4536-43).
Additional details about the specific tasks can be found in the Annual progress reports for Year 1 and 2.
Statement of Work for Year 3 (BC Cancer Agency component)
The tasks and timeline for the Vancouver site for Year Three are as follows:
1-Month 25-33. For markers that show promise in distinguishing between cancer vs. non cancer CT lesions, pre-validate whether the markers can distinguish between T1NOMO versus T1N+/M1 lung cancer. 2-Month 25-33.Test for discrimination between PET positive versus PET negative Stage IA lung cancers as well as PET positive benign lung nodules detected by screening spiral CT. 3-Month 25-36. Test validation specimens for clinical applications 1 and 2 to determine if the markers meet the statistical criteria compared to other biomarkers in the pre-validation study.
Work accomplished:
Overdue Work from Year two:
Due to a delay in IRB approval, most tasks were delayed by approximately 6 months. All tasks from year one and two have been completed with the exception of 1-7 and 2-2, which are validation tasks. Due to the continued identification of potential candidates these two tasks remain in progress as we attempt to identify the most robust candidates with potential clinical application. Year three tasks are all underway and the work accomplished on outstanding tasks as well as those for the past year are summarized below.
Year 1 Tasks:
Task 6 -Assay over-expressed miRNAs in blood from patients of the 100 tumor specimens and determine concordance with tumor tissue. Status: Completed Work accomplished: Analysis of miRNA sequencing data identified 13 miRNAs deregulated in over 85% of tumors relative to matched non-malignant tissue, 8 of which were over-expressed. miRNAs that also showed a high frequency of alteration (>80%) in the TCGA cohort (n=4) were assessed in blood samples. Concordance between miRNA expression in plasma and tumor tissue varied between miRNAs, but all miRNAs showed a strong correlation (r>0.55) between blood and tissue levels.
Task 7 -Assay miRNA in blood from 50 patients with benign CT detected lung nodules and compare the levels with patients with lung cancer. Status: On going Work accomplished: Due to small amount of RNA that can be extracted from blood samples (~200ng) and the nature of miRNA qPCR, which requires separate reverse transcriptase reactions using 10ng or RNA for each miRNA, we are limited in the number of miRNA that we can test in these blood samples. To ensure that we can test the candidates with the best promise to differentiate between benign and malignant lung nodules, testing in this cohort will be done as one of the final validation steps. The four miRNAs identified in task 6 along with a list of miRNA that differentiate metastatic from non-metastatic tumors and validate in blood samples (see Year 3 task 1) will be tested in these samples. Task 8 -Select hypermethylated genes for further investigation in blood by Dr. Gazdar. Status: Completed Work accomplished: Our short list of differentially methylated genes was integrated with gene expression data and promising candidate genes with concordant methylation and expression changes were analyzed/validated by Dr. Gazdar at UTSW in his sub-contract.
Year 2 Tasks:
Task 1-Integration of miRNA, mutation status, methylation, gene expression and published data to deduce over-expressed genes to identify potential protein targets for investigation in blood by Dr. Hanash Status: Completed Work accomplished: Integration of the multiple genomic dimensions has identified a number of candidate oncogenes with DNA level alterations and corresponding changes in gene expression. These include YEATS4, MARK2 and ELF3 to name a few. These targets and others have been sent to Dr. Hanash for investigation of protein levels within blood to determine whether any candidates have potential application as biomarkers. Validation of one of Dr. Hanash's protein biomarkers (pro Surfactant B) was made possible through the use of blood samples from Dr. Stephen Lam's Pan-Canadian Early Cancer Detection Study and a manuscript detailing these findings has been published in the Journal of Clinical Oncology.
Task 2-Select the best over-expressed miRNA for assessment using aliquots of specimens assigned for pre-validation studies for clinical applications 1 and 2. Status: On going Work accomplished: Following identification of candidates and successful validation in external cohorts such as the TCGA, promising markers are assessed in pre-validation specimens to determine the most robust and clinically relevant candidates for further testing in precious blood specimens. miRNAs altered in >85% of tumors have been validated in these specimens and miRNA identified as differentially expressed between metastatic and non-metastatic (for more details see Year 3, task 1) tumors are currently being assessed.
Year 3 Tasks:
Task 1-For markers that show promise in distinguishing between cancer vs. non cancer CT lesions, prevalidate whether the markers distinguish between TINOMO versus TIN+/MI lung cancer. Status: On going Work Accomplished: Using miRNA seq profiles from the 30 locally invasive and 30 metastatic tumors we identified miRNAs that were 1) differentially expressed between tumors and non-tumor tissues and 2) differentially altered between the locally invasive and metastatic tumors. This analysis yielded 12 miRNA, of which 5 were specific to metastatic tumors and 7 to the locally invasive cohort. Target analysis of these miRNAs revealed a number of common targets involved in the TGFB signaling pathway, which is known to play a role in invasion and metastasis ( Figure 3 ). The ability of this panel of miRNAs to accurately discriminate between T1N0M0 and T1N+/M+ cases is currently being assessed in pre-validation sets and successful candidates will be further examined in blood samples (Year 1, task 7) to determine their potential as blood based biomarkers.
Task 2-Test for discrimination between PET positive versus PET negative Stage IA lung cancers as well as PET positive benign lung nodules detected by screening spiral CT. Status: Complete Work Accomplished: miRNA profiles were generated on an Agilent microarray for 30 formalin fixed paraffin embedded Stage I/II NSCLC cases (14 PET negative and 16 PET positive). To determine whether any of our candidate markers identified in earlier tasks (year 1, task 6 and year 3, task 1) are capable of discriminating between PET positive and PET negative cases, we assessed the levels of these 16 miRNA in this cohort. Of the 16 candidates, all but hsa-mir-4772 (associated with metastatic tumors) was measureable on the array. Four miRNA, let-7g, mir-29a, -34b and -141 were associated with PET status (Mann Whitney U, p<0.05); however none passed multiple testing correction (Table 3) .
Task 3-Test validation specimens for clinical applications 1 and 2 if the markers meet the statistical criteria compared to other biomarkers in the pre-validation study. Status: Awaiting candidates for analysis Work Accomplished: As testing of candidates in the final validation cohorts has yet to be completed, statistical analysis on successful candidates has not yet been performed.
KEY RESEARCH ACCOMPLISHMENTS:
Year 1  Nothing to report. In year 1 we focused on collecting samples, extracting genetic material and completing multi-omics profiling.
Year 2
 Identified 18 microRNAs (12 over-expressed and 6 under-expressed) that were altered in at least 90% of tumors and confirmed their ability to accurately discriminate between tumor and non-malignant tissue by Principal component analysis (See Table 1 and Figure 1 ). OE  100%  0%  95%  0%  99%  0%  hsa-mir-96  OE  98%  0%  100%  0%  99%  0%  hsa-mir-130b  OE  95%  0%  100%  0%  97%  0%  hsa-mir-183  OE  94%  0%  100%  0%  95%  0%  hsa-mir-345  OE  94%  2%  95%  0%  94%  1%  hsa-mir-877  OE  94%  2%  95%  0%  94%  1%  hsa-mir-331  OE  94%  0%  91%  5%  93%  1%  hsa-mir-182  OE  94%  0%  86%  0%  92%  0%   8   hsa-mir-708  OE  89%  0%  100%  0%  92%  0%  hsa-mir-141  OE  92%  0%  86%  0%  91%  0%  hsa-mir-193b  OE  89%  3%  95%  0%  91%  2%  hsa-mir-301b  OE  89%  0%  95%  0%  91%  0%  hsa-mir-144  UE  0%  98%  0%  100%  0%  99%  hsa-mir-30a  UE  0%  97%  0%  100%  0%  98%  hsa-mir-451a  UE  0%  97%  0%  91%  0%  95%  hsa-mir-143  UE  0%  97%  0%  82%  0%  93%  hsa-mir-486  UE  0%  94%  0%  86%  0%  92%  hsa-mir-101  UE  0%  89%  0%  95% A.
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cases accurately separated tumor and non-malignant tissue (B). Blue dots represent non-malignant tissue while red dots represent tumor samples.  Validation of the 18 miRNAs in the TCGA cohort identified four miRNAs (miR-130b, -141, and -183 -210) frequently overexpressed in tumors. All four miRNA were detectable in blood and assessment of these candidates in pre-validation samples showed a strong correlation (r>0.55) between blood and tissue levels. Area under the curve analysis of these four miRNAs revealed all miRNAs were able to accurately discriminate between tumor and non-malignant tissue (r>0.98, p<0.0001) (Figure 2 ).
Figure 2.
Figure 2. Receiver operator characteristics of validated miRNAs. Area under the curve analysis of the four miRNA frequently altered in tumors relative to non-malignant tissue and validated in TCGA cohort, revealed that all miRNAs are able to accurately discriminate between tumor and nonmalignant tissue with high specificity and sensitivity.
 Integration of multiple genomic levels (mutation, methylation and gene expression) identified candidate oncogenes (YEATS4, ELF3) and tumor suppressors (SIRPA, EYA4) that have been validated in our lab. Manuscripts detailing the biological roles of these genes have been published or are in preparation (see bibliography), and the published manuscripts for YEATS4 and EYA4 are appended.
 Performed a validation study on one of Dr. Hanash's blood biomarkers -Pro-surfactant protein B (pro-SFTPB) using 2,485 blood samples from the Pan-Canadian Early Lung Cancer Detection Study. Plasma level of pro-SFTPB was found to be an important independent predictor of lung cancer, and a valuable addition to existing lung cancer risk prediction models (J Clin Oncol 31(36):4536-43, appended).
Year 3
 Identified 12 miRNAs that were differentially altered between the locally invasive and metastatic tumors (T1NOMO versus T1N+/MI); 5 specific to metastatic tumors and 7 to the locally invasive cohort and validated in an external cohort (Table 2) . Target analysis revealed a number of common targets involved in the TGFB signaling pathway (Figure 3 ), which is known to play a role in invasion and metastasis. . miRNAs associated with metastasis target the TGFB pathway. Pathway analysis of the 12 miRNAs differentially altered between metastatic and locally invasive adenocarcinomas revealed enrichment of mRNA targets in the TGFB pathway, a pathway known to be involved in epithelial to mesenchymal transition and metastasis.  Identified 4/16 of our miRNAs; let-7g, mir-29a, -34b and -141 to be associated with PET status (Mann Whitney U, p<0.05). Although these miRNAs did not pass multiple testing correction  Pro-SFTPB levels are significantly higher in interval cancers and malignant lung nodules versus benign lung nodules and those with no lung nodules.
CONCLUSION
Despite delayed IRB approval which caused a six month setback, we have completed the tasks in the statement of work. Our analysis has identified numerous potential candidates, some of the most promising of which are panels of miRNAs that distinguish tumor tissue from non-malignant tissue and aggressive tumors (metastatic) from less aggressive tumor (non-metastatic). These panels serve as the basis for future studies to determine their potential clinical relevance as blood based predictive, diagnostic or prognostic biomarkers for lung cancer. Through this grant, we have been able to collect unique cohorts of tumor and blood specimens for discovery and validation of biologically based biomarkers. We have identified promising miRNA candidates and will continue to assess the clinical potential of these and other candidate biomarkers over the next few years.
PUBLICATIONS, ABSTRACTS AND PRESENTATIONS:
A total of 22 peer reviewed journal publications and 12 published abstracts will be generated from grant # W81XWH-10-1-0634 . Specifically, 10 manuscripts and 12 abstracts have been published as a result of the work from this grant. An additional 5 manuscripts are currently in preparation or under review. These items are listed below. Moreover, the data published from this grant has enabled further analyses of tumor genomes in additional projects beyond the scope of W81XWH-10-1-0634 (7 publications listed below).
Peer-reviewed Scientific journals (n = 10):
Interval In an effort to identify novel biallelically inactivated tumor suppressor genes (TSGs) in sporadic invasive and preinvasive non-smallcell lung cancer (NSCLC) genomes, we applied a comprehensive integrated multiple 'omics' approach to investigate patientmatched, paired NSCLC tumor and non-malignant parenchymal tissues. By surveying lung tumor genomes for genes concomitantly inactivated within individual tumors by multiple mechanisms, and by the frequency of disruption in tumors across multiple cohorts, we have identified a putative lung cancer TSG, Eyes Absent 4 (EYA4). EYA4 is frequently and concomitantly deleted, hypermethylated and underexpressed in multiple independent lung tumor data sets, in both major NSCLC subtypes and in the earliest stages of lung cancer. We found that decreased EYA4 expression is not only associated with poor survival in sporadic lung cancers but also that EYA4 single-nucleotide polymorphisms are associated with increased familial cancer risk, consistent with EYA4s proximity to the previously reported lung cancer susceptibility locus on 6q. Functionally, we found that EYA4 displays TSG-like properties with a role in modulating apoptosis and DNA repair. Cross-examination of EYA4 expression across multiple tumor types suggests a cell-typespecific tumorigenic role for EYA4, consistent with a tumor suppressor function in cancers of epithelial origin. This work shows a clear role for EYA4 as a putative TSG in NSCLC.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality in the world, accounting for 1.5 million deaths each year. 1 Over 80% of lung cancers are non-small-cell lung cancer (NSCLC), of which adenocarcinomas (ACs) and squamous cell carcinomas (SqCCs) are the predominant subtypes. 2 Owing to late-stage diagnosis and paucity of effective treatments, the 5-year survival for lung cancer patients is o15%. There remains an urgent, worldwide need for early detection markers and improved chemoprevention and therapeutic regimens for this disease.
Multiple genetic mechanisms contribute to the evolution of cancer genomes; therefore, integration of data from multiple 'omics' levels for an individual tumor represents a powerful approach for discovering genes selectively altered in tumors. Within individual tumor genomes, it is likely that genes selectively disrupted sustain biallelic or 'two-hit' disruptions, as commonly observed with many tumor suppressor genes (TSGs).
3 Therefore, we hypothesized that genes (i) sustaining frequent, high level and two-hit gene dosage and/or DNA methylation alterations and (ii) undergoing concomitant alterations at the mRNA level would be indicative of genes selectively inactivated in lung tumors and therefore relevant to lung tumor biology.
Applying this rationale to genome-wide copy number, DNA methylation and gene expression profiles from a large panel of NSCLC tumor clinical specimens with patient-matched, nonmalignant parenchymal tissues, we discovered a novel putative lung cancer TSG Eyes Absent 4 (EYA4). EYA4, a putative oncogene in tumors of neural origin, is an atypical, dual-functioning protein phosphatase that functions in mediating DNA repair, apoptosis and innate immunity in response to DNA damage, damaged cells and viruses. Our findings suggest a dual role for EYA4 in carcinogenesis, likely dependent on cancer cell type of origin and strongly supportive of a tumor suppressor role in lung cancer. Collectively, our findings illustrate the utility of a multidimensional tumor systems approach to cancer 'omics' research applied to the discovery of novel lung cancer TSGs.
RESULTS
Few genes are inactivated by homozygous deletion in lung ACs
We sought to investigate whether homozygous deletion (HD) is a mechanism of recurrent gene inactivation in a panel of AC tumors and patient-matched, non-malignant lung parenchyma tissues (n ¼ 77 pairs), using Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, CA, USA). We calculate that a DNA copy number (CN) of 0.4 should represent an HD if tumor cell content is 80% in a given specimen. In our panel of 77 AC specimens, we identified only two genes, CDKN2A and CDKN2B, that were HD at CN o0.4 in more than two specimens, consistent with previous reports for these genes. 4 To compensate for cytological heterogeneity within tumors, we relaxed our HD detection threshold to CN o1.0, which yielded no further HD genes (Supplementary Table S1 ). Therefore, we reasoned that biallelic inactivation of TSGs must occur through a combination of other mechanisms such as DNA hypermethylation and singlecopy loss.
EYA4 is frequently inactivated by deletion and hypermethylation in lung AC To identify genes disrupted by deletion and promoter hypermethylation, we obtained genome-wide DNA methylation profiles (Illumina Infinium HumanMethylation27, Illumina, San Diego, CA, USA) for this same panel of 77 AC tumor pairs. We searched for frequent (415%) and concurrent CN loss and promoter hypermethylation events. We identified 114 genes that were frequently deleted and hypermethylated in the same tumor (Supplementary  Table S2 ), which included both previously reported and novel putative lung TSGs. Integration with expression data revealed 37 genes that were significantly underexpressed, lost and hypermethylated in our cohort (indicated in Supplementary Table S2 ). Of these, we focused on the putative TSG EYA4, based on the high frequency of biallelic disruption (19.5%) and significant underexpression (32.5%) in our cohort ( Figures 1a and b) , frequency of inactivation by multiple mechanisms in other epithelial cancers and proximity to the lung cancer susceptibility locus at 6q23. [5] [6] [7] [8] [9] Overall, 67.5% of our AC panel sustained allelic inactivation of EYA4 by either CN loss (26%) or by promoter hypermethylation (61%) (e.g., Figure 1a ). We calculated the probability of observing a twohit DNA level and gene expression event in a single tumor pair by multiplying the proportion of any probe we observed undergoing hypermethylation, CN loss and underexpression of alterations. 10 The average proportion of each of these events occurring in our cohort of 77 AC tumor pairs was: hypermethylation 0.0825, CN loss 0.1614 and underexpression 0.1176. Therefore, the probability of observing a two-hit inactivating DNA level alteration and underexpression event for a single gene in a tumor sample from our cohort was 0.0016. Moreover, the probability of randomly observing the frequency for which we detect EYA4 inactivated by these mechanisms is extremely low (1.433 Â 10 Figure S1 ). These findings suggest that EYA4 inactivation is strongly selected for in AC. We validated mechanistic control of EYA4 expression by DNA methylation by observing re-expression of hypermethylated EYA4 in AC cancer cells after treatment with a demethylating agent (5-azacytidine) (Supplementary Figure S2 and Supplementary Table S3 ).
EYA4 is inactivated by CN loss and hypermethylation in both major NSCLC subtypes We also found that EYA4 was significantly underexpressed (Po0.0001) in a panel of 45 SqCC tumors compared with 67 histologically normal bronchial epithelia samples, and also hypermethylated (Po0.02) in a panel of 8 SqCC tumors compared with 8 bronchial epithelia samples for which DNA methylation profiles were available (Figures 1c and d) . We also applied our criteria to DNA methylation data downloaded from the recently published lung squamous The Cancer Genome Atlas (TCGA) study. 11 We limited our validation only to those TCGA SqCC tumors with available matched normal specimens (n ¼ 27 tumor pairs). We found that 15-37% of these tumors had a 20% or greater methylation increase at EYA4 loci compared with their matched normal counterparts. We further examined an external set of NSCLC specimens (n ¼ 883 tumors) from four additional data sets and found that 14% (n ¼ 123 tumors) exhibited deletion of EYA4. [12] [13] [14] [15] Reduced EYA4 expression was confirmed in two additional independent NSCLC cohorts for which matched normal references were available (Supplementary Figure S3) . 16, 17 Taken together, these results strongly indicate that EYA4 is disrupted in both major subtypes of NSCLC.
Mutation is not a major mechanism of EYA4 disruption We evaluated whether DNA sequence mutations occurred in EYA4 by analyzing the Catalogue of Somatic Mutations in Cancer (COSMIC) database (http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/) and also by sequencing all 20 coding exons of EYA4 in a panel of 38 AC cell lines (listed in Supplementary  Table S3 ). COSMIC analysis revealed 20 confirmed somatic mutations (3%) in a cohort of 639 clinical NSCLC samples. In lung cancer cell lines, we identified only one likely pathogenic variant in exon 7 (EYA4: c.385G4C, p.Gly129Arg) of sample H23 that converts a Gly codon to Arg (Figure 2a ). This mutation is predicted by PolyPhen2 and SIFT to be deleterious 18 based on the nature of the amino-acid change and the conservation at that residue. To examine the impact of this mutation in these cells, we assessed the locus for gene dosage, loss of heterozygosity, DNA methylation, and mRNA and protein expression. These analyses revealed that EYA4 is diploid in H23, is not hypermethylated and resides within an area of acquired uniparental disomy. This is consistent with our observation of a homozygous EYA4 mutation and moderate mRNA expression in these cells, but no detectable EYA4 protein, indicating perhaps that this mutation may impact protein stability (Figure 2b ). Given the frequency of observed CN loss (43%) or hypermethylation (40%) events affecting EYA4 relative to low frequency of EYA4 mutations (3%), we posit that sequence level mutations are not a major mechanism contributing to EYA4 disruption in lung cancer.
EYA4 inactivation is an early event in lung cancer To assess whether somatic DNA level disruptions of EYA4 occur early in tumorigenesis, we evaluated gene dosage levels in 20 carcinoma in situ (CIS) specimens. These rare samples were collected by fluorescent bronchoscopy (Figure 3a ) and represent a stage of cancer development typically too early for detection using routine imaging procedures. Deletion of EYA4 was observed in 35% of these preinvasive squamous CIS lesions, supporting the loss of EYA4 as an early neoplastic event (Table 1) . Transcriptome sequencing data generated in a previous study 19 revealed reduced EYA4 expression in CIS and SqCC samples compared with histologically normal bronchial epithelial cells (Figure 3b ). At the level of DNA methylation, we detected EYA4 hypermethylation in 40% (n ¼ 10) of cytologically normal bronchial epithelia from patients with NSCLC as well as in one high-risk patient with chronic obstructive pulmonary disease (Figure 3c ). Inactivation of EYA4 in the precursors of disease implicates EYA4 as an early event in lung tumorigenesis.
EYA4 exhibits functional characteristics of a lung cancer TSG Stable EYA4 knockdown (EYA4kd) of lung lymphoblastoid (HCC-1954BL) cell lines and ectopic overexpression (EYA4 þ ) of AC cells (H2122, H2405) were established for all in vitro and in vivo assays (Supplementary Figure S4A) . AC lines were chosen based on the lack of detectable EYA4 protein expression (Supplementary Figure S2E) , and lymphoblastoids as karyotypically normal models highly amenable to the assays performed. Notably, while more appropriate non-malignant lung models were available, including human bronchial epithelial cells, small airway epithelial cells and fetal lung fibroblasts (WI-38), we found these cells unsuitable for subsequent analyses because of unselectability based on our knockdown construct (human bronchial epithelial cells), or drastic changes to cell morphology and behavior (WI-38) upon EYA4 knockdown. EYA4 knockdown was also attempted in nontransformed small airway epithelial cell lines; however, loss of EYA4 in these normal epithelial cells was not tolerated and resulted in cellular senescence, as described previously 20 (data not shown).
EYA4 loss negatively impacts DNA repair and genomic instability EYA4 is an atypical phosphatase, containing a C-terminal tyrosine (Tyr) and a recently discovered N-terminal threonine (Thr)-phosphatase domain, that has distinct functions and catalytic activity conditions. 21, 22 In response to double-stranded breaks, EYA4 dephosphorylates the Tyr-142 residue of H2AX facilitating phosphorylation of Ser-139 of H2AX (forming gH2AX), leading to the recruitment of DNA repair complex components to sites of double-stranded break. 21, [23] [24] [25] [26] We assessed levels of gH2AX and Tyr-142 phosphorylation of H2AX in EYA4kd and control cells following DNA damage induced by irradiation. Cells lacking EYA4 accumulate markedly more and longer lasting gH2AX than controls (Figure 4a ). Consistently, we observed markedly higher levels of Tyr-142-phosphorylated H2AX in EYA4kd cells in response to irradiation compared with empty vector cells (Figures 4b-d) . However, restoration of EYA4 expression in EYA4 þ cancer cell models had no significant effect on gH2AX levels following irradiation ( Supplementary Figures S4C and D) . These results suggest that while EYA4kd in karyotypically normal cells results in EYA4: c.385G > C p.Gly129Arg (a) Sample H23 shows a coding sequence mutation in EYA4. All exons and proximal intronic sequences were screened in 38 AC lines for mutations by Sanger sequencing. A likely pathogenic missense mutation in exon 7 was identified (EYA4: c.385G4C, p.Gly129Arg), which is shown along with wild-type H920. (b) This mutation is associated with a lack of protein production as shown by the immunoblot, despite mRNA production by H23. H2122 and H920 are negative and positive controls, respectively, whereas WI38 is a normal fibroblast reference line. This suggests that the mutation may result in premature protein degradation.
increased double-stranded break during DNA damage onslaught (as measured by gH2AX accumulation), EYA4 restoration in lung cancer cells is not sufficient to modulate gH2AX-mediated repair. This is likely due to high frequency of mutations in key DNA repair genes, such as TP53 or CDKN2A (both mutated in H2122 and H2405).
To further explore the relationship between EYA4 and DNA damage response in cancer cells, we examined the effect of a DNA damage-inducing agent, cisplatin, in response to EYA4 overexpression. We observed that cancer cells made to overexpress EYA4 were reproducibly more resistant to cisplatin than those without EYA4, indicating that in the absence of EYA4, cancer cells appear more sensitive to DNA damage onslaught (Figure 4c ). Given the observed effect of EYA4 on DNA repair and response to DNA damage, we hypothesized that tumors with reduced EYA4 expression would exhibit a greater extent of genomic instability. To test this, we compared the proportion of the genome encompassed by segmental CN alterations in 83 lung AC tumors with high and low EYA4 gene expression (3.2-fold expression difference between groups). This comparison revealed a significant trend toward increased genomic instability in tumors with low EYA4 expression (P ¼ 0.0413, two-tailed U-test; Figure 4d ), an association further supporting a role for EYA4 in DNA damage repair. We found a similar trend in a second, independent lung AC cohort (n ¼ 193) downloaded from the Memorial Sloan Kettering Cancer Center 14 (P ¼ 0.0027) (Figure 4e ).
EYA4 loss results in decreased induction of apoptosis. Previous literature implicates EYA4 as a modulator of apoptotic response. 25, 27 We tested this by fluorescence-activated cell sorting (FACS) of annexin V/propidium iodide (AV/PI)-stained EYA4 modulated and control cells following serum starvation. EYA4 þ cancer cells displayed no differences in the percentage of early or late apoptotic cells (Supplementary Figure S4B) . As cancer cells have heavily disrupted genetic backgrounds that likely interfere with apoptotic pathways, we examined the effect of EYA4 expression on apoptosis of karyotypically normal EYA4kd lines and controls. FACS results indicated that, contrary to our cancer cell lines, EYA4kd cells displayed a marked and reproducible decrease in the numbers of early (AV þ /PI À ) and late (AVþ /PI þ ) apoptotic cells compared with pLKO (26.6±4.6% for control vs 14.5±1.7% for EYA4kd) (Figures 5a-c) , indicative of a proapoptotic role for EYA4. Previous reports have suggested that a TSG role for EYA4 may be mediated via its role as a transcriptional coactivator. 5, 6, 27, 28 To identify genes correlated with EYA4 expression (and potentially activated by EYA4), profiles for the 10 highest and 10 lowest EYA4-expressing normal bronchial specimens were compared using the significance analysis of microarrays algorithm. 29 Twenty-eight genes potentially coactivated by EYA4 were identified (q-value percentage threshold of 5%) (Supplementary Table S4 ). One of the most highly correlated of these genes was GADD45a, which has a role in the apoptotic program, DNA damage and cell cycle arrest. 30 Indeed, we found that following serum starvation, GADD45a expression was attenuated in EYA4kd cells compared with control cells (Figure 5d ). , CIS (n ¼ 5) and invasive SqCC (n ¼ 6) samples. EYA4 is underexpressed in the CIS group (Po0.05 compared with normal) and remains reduced in SqCC. (c) EYA4 is hypermethylated in histologically normal bronchial epithelia of NSCLC patients (n ¼ 10) compared with patients without cancer (n ¼ 5) as detected by methylation-specific polymerase chain reaction, providing compelling evidence that inactivation of EYA4 is a very early event. One high-risk chronic obstructive pulmonary disease (COPD) patient is indicated (*), and positive (H1395) and negative (HCC-2935) controls are shown.
EYA4 is inactivated biallelically in sporadic lung cancer IM Wilson et al
These results are intriguing, although not explicitly demonstrative of any mechanistic link between the two. The observed relationship between EYA4 and GADD45a expression warrants further exploration.
Restoration of EYA4 expression inhibits tumor growth in vitro and in vivo
Although restoration of EYA4 expression in two AC cell lines had little effect on DNA damage and apoptosis, we sought to determine whether EYA4 expression had any effect on anchorage-independent growth and tumor growth in vivo. Indeed, our EYA4 þ AC cell lines had significantly impaired cell growth and colony formation ability as measured by soft agar colony formation (Figures 6a and b) . When H2122 EYA4 þ was implanted into non-obese diabetic/severe-combined immunodeficiency mice, EYA4 overexpression significantly impeded tumor growth (Figure 6c and Supplementary Table S5 ).
EYA4 exhibits cell-type-specific expression Intriguingly, in addition to its putative TSG functions in various cancers, EYA4 has also been described as an oncogene in neural cancer. 31 We evaluated cancer cell-type-specific expression of EYA4 in a panel of over 350 cancer cell lines encompassing a variety of cancer types (Supplementary Table S6 ). We detected high EYA4 expression in cancer cells derived from sarcomas, autonomic ganglia and brain, relative to epithelial cancers such as the lung, gastrointestinal, pancreatic, head and neck and colorectal tumors (Figure 6d ). These findings are consistent with a TSG role for EYA4 in lung cancer, and interestingly support a dual role (TSG or oncogenic) for EYA4 that is likely dependent on the cell type of origin. Of note, EYA4 was not differentially expressed between small-cell lung cancer, which is thought to be derived from pulmonary neuroendocrine cells, and NSCLC (Figure 6e ).
Clinical relevance of EYA4
We performed a Mantel-Cox survival analysis in two external lung AC data sets with survival data (GSE3141 16 and GSE12428 32 ), and found that reduced EYA4 expression was significantly and consistently associated with poor survival (Figures 7a and b) , underscoring the clinical relevance of EYA4 expression to AC patient prognosis. Although EYA4 single-nucleotide polymorphisms (SNPs) have not been previously associated with familial lung cancer risk, given the frequency of EYA4 inactivation in sporadic lung cancer, and the proximity of EYA4 to the previously refined lung cancer susceptibility locus by You et al. 33 and BaileyWilson et al. 34 at 6q23-25, we sought to evaluate the significance of EYA4 SNPs in familial lung cancer. A Cochrane-Armitage Trend test corrected for multiple comparisons (Po0.05) revealed that a cluster of SNPs in the EYA4 gene (rs7743259, rs159420, rs35689029, rs1878551 and rs2677826) were indeed enriched in a panel of familial NSCLC cases (Figures 7c and d and  Supplementary Table S7) . 35 
DISCUSSION
Cancer genomes are frequently disrupted at multiple 'omic' levels-all of which may be differentially impacted by unique selective pressures occurring throughout the tumorigenic process. Within these tumor systems, it is likely that genes critical to abrogating tumor development undergo biallelic ('two-hit') disruption, as commonly observed with many TSGs. If two-hit events occur by differing mechanisms, the frequency of alteration for that gene may be low when assessed for only one mechanism, and thus likely overlooked. However, when multiple dimensions of disruption are considered simultaneously, alteration of the two-hit gene in question may be detected at a high frequency. Therefore, identification of these events in the complicated genomes of epithelial malignancies, such as lung cancer, requires the simultaneous interrogation of multiple 'omics' level data sets.
We applied such a multidimensional approach to a panel of patient-matched, paired tumor and non-malignant parenchymal samples from patients with NSCLC, and identified EYA4, a gene frequently and often simultaneously disrupted by CN loss and promoter hypermethylation in multiple clinical cohorts, representing over one thousand NSCLC tumors. Disruption of EYA4 was also detected at the level of CN loss in SqCC precursor CIS specimens, and by promoter hypermethylation in cytologically normal small airway epithelia from patients with NSCLC. In addition to invasive lung AC, promoter hypermethylation of EYA4 was also recently reported in atypical adenomatous hyperplasia and AC in situ (formerly known as bronchioloalveolar carcinoma), collectively pointing to the importance of EYA4 in cancer initiation events of both major NSCLC subtypes. 5, 36 Interestingly, early inactivation of EYA4 by hypermethylation has been associated with Barrett's esophagus-related tumorigenesis, sporadic and colitic neoplasia in chronic ulcerative colitis and is currently being explored as an epigenetic biomarker for colorectal and pancreatic cancer screening.
6,9,37 Given our findings, exploration of EYA4 as a maker for early NSCLC detection is warranted.
Consistent with TSG function, reconstitution of EYA4 in NSCLC cell lines decreased soft agar colony formation and in vivo tumor growth. And, although we found lower EYA4 expression associated with increased sensitivity to DNA-damaging cisplatin treatment in NSCLC cell lines, and increased proportions of genome altered in lung tumors, functional impact on both DNA repair and apoptosis was only significant when EYA4 was abrogated in karyotypically normal cell models as opposed to restored in NSCLC models. Given the multiplicity of genomic aberrations in lung cancer cell lines models, particularly affecting DNA repair and apoptotic proteins (e.g., p53, ATM, PTEN), we were not surprised that modulation of one gene failed to cause significant phenotypic changes. However, in the context of an early tumor suppressor role for EYA4, it is possible that inactivation of EYA4 could lead to increased lung cancer risk by promoting an impaired response to DNA-damaging agents such as cigarette smoke.
Although multiple lines of evidence in several cancers are supportive of a TSG role, EYA4 is also an overexpressed putative oncogene in tumors of neural origin. 31 This discrepancy may be inherent to the unique and recently discovered dual phosphatase properties of EYA4, whereby a Tyr-phosphatase domain at the C terminal and a Thr-phosphatase domain at the N-terminal function independently and under distinct catalytic conditions. 21, 22 Mutations of the Thr-phosphatase domain, but not the Tyr-phosphatase domain, have been shown to abolish the ability of EYA4 to enhance the innate immune response to viruses and undigested double-stranded DNA from apoptotic cells, 22 and mutations to the Tyr-phosphatase domain, which normally promotes DNA repair in response to double-stranded break, are linked with neuronal developmental defects and deafness. Our findings in over 350 cancer cell lines from multiple tumor types demonstrate that EYA4 is expressed at substantially lower levels in epithelial tumors compared with sarcomas or neurally derived tumors, supporting the seemingly contradictory findings and pointing towards an either tissue-specific or dual TSG or oncogene role for EYA4 in cancer development. In the context of lung cancer, Figure 7 . EYA4 is associated with lung cancer risk and poor survival. (a) Kaplan-Meier plot. Survival information from an external data set (GSE3141) for the highest and lowest tertiles (of EYA4 expression) was compared using the Mantel-Cox log test. EYA4 is significantly associated with poorer prognosis (P ¼ 0.007). (b) The analysis was repeated using another external data set (GSE12428). Low EYA4 expression is significantly associated with poor prognosis (P ¼ 0.018). (c) EYA4 SNPs are significantly associated with familial lung cancer risk. Genotype data for 6q-linked familial lung cancers (n ¼ 194) and unrelated non-cancer controls (n ¼ 217) were compared to determine whether EYA4 allelotypes associate with risk. Five SNPs depicted were significantly associated (Po0.05). Gene structure is shown in blue. (d) The allele associated with an increased risk is described as the risk allele. Demographic features, stage and histology are unavailable for the external data sets for panels a and b.
EYA4 is inactivated biallelically in sporadic lung cancer IM Wilson et al inherited or acquired EYA4 disruption could potentially result in uncontrolled cellular division, accumulation of genetic damage from genotoxic agents such as cigarette smoke or impaired innate immunity from double-stranded DNA released from damaged respiratory cells.
The Genetic Epidemiology of Lung Cancer Consortium (GELCC) has identified a susceptibility locus on 6q, which contains the overexpressed candidate oncogene, RGS17. [33] [34] [35] [38] [39] [40] [41] We discovered a cluster of SNPs within EYA4, immediately adjacent to this susceptibility locus, that are significantly associated with lung cancer risk in familial lung cancer cases. Patterns of EYA4 disruption in lung cancer are similar to other important TSGs involving both sporadic and familial cancers, which also frequently sustain biallelic inactivation. 42 For example, BRCA1/2 germline mutations and somatic promoter hypermethylation events occur in familial breast tumors, whereas biallelic inactivation by hypermethylation and deletion is common in sporadic breast cancer. [42] [43] [44] Taken together with evidence strongly indicating selective inactivation of EYA4 in sporadic lung cancer, our findings raise the intriguing possibility of a novel familial lung cancer susceptibility gene.
In summary, the prevalence of biallelic inactivation of EYA4 in NSCLC, its multiple tumor suppressor functions and association with survival in sporadic lung cancers and familial lung cancer risk suggest that EYA4 is important to NSCLC development, and may be a promising marker for early lung cancer detection. Considering its diverse biological functions and likely multifaceted role in lung carcinogenesis, the development of appropriate in vivo models to assess the role and potential manipulation of EYA4 pathways in lung cancer are needed, albeit highly challenging.
MATERIALS AND METHODS
Sample collection
Lung tumors and adjacent non-malignant tissue were obtained from freshly resected tumors and microdissected so that the tumor cell content exceeded 80%, and DNA and RNA were extracted using standard protocols. Bronchial epithelial specimens from airways r2 mm diameter, and biopsy of locally invasive SqCC and CIS specimens, were obtained during bronchoscopy as described previously. 19 This study was approved by the Review of Ethics Board of the University of British Columbia and the British Columbia Cancer Agency.
Molecular profiling
Genomic DNA for 83 lung ACs and matched non-malignant lung tissues from the same individuals was hybridized to Affymetrix SNP 6.0 arrays. Raw data were processed, segmented and CN alterations called using Partek Genomic Suite Software (Partek, Missouri, MO, USA), as defined previously. 12 SNP array data for the BCCA tumors is in compliance with the MIAME guidelines and has been deposited in the Gene Expression Omnibus. DNA methylation profiling for AC tumor pairs (n ¼ 77) and cell lines (n ¼ 38) was performed using the Illumina Infinium HumanMethylation27 chip, and SqCC tumor pairs (n ¼ 8) on Illumina GoldenGate Cancer chip (Illumina) was performed using methods described previously, including bisulfite conversion using EZ DNA methylation-Gold kit (Zymo Research, Irvine, CA, USA). 45 Array data were analyzed and methylation levels determined using GenomeStudio software. b ¼ Methylated signal/(methylated signal þ unmethylated signal þ a); b with a detection P-value r0.05 were included. Hypermethylation was defined as 420% b-value difference in tumor relative to patient-matched nonmalignant control. Methylation validation was performed by real-time methylation-specific polymerase chain reaction as described previously using the EYA4 primers, 5 0 -TTGCGTAAGTGCGAGGTTGTC-3 0 (forward), 5 0 -AACA ACGACAACTTCACGTAA-3 0 (reverse), and 5 0 -FAM TCGTTTTCGGTTTTCGC GTAA BHQ1-3 0 (probe), using non-methylated MYOD1 as an internal reference standard. Standard methylation-specific polymerase chain reaction was performed using primers specific to methylated and unmethylated forms of EYA4 as described previously. 28 Re-expression of methylated EYA4 following demethylation by 10 mM 5-azacytidine every 2 days (Sigma Aldrich, St Louis, MO, USA) for 6 days was validated in NCI-H1395 and NCI-HCC2935 cells, otherwise cultured as per ATCC (Manassas, VA, USA) directions. Gene expression profiles were generated for AC tumornormal pairs on the Illumina WG6 microarray (Illumina). EYA4 DNA methylation status was also validated in an external data set downloaded from The Cancer Genome Atlas Data Portal (https://tcga-data.nci.nih.gov/tcga/) for all SqCC specimens that had methylation profiles for tumor and matched nonmalignant specimens (n ¼ 27 pairs). 46 Forty-five SqCC Affymetrix expression profiles (GSE3141) and 67 non-malignant bronchial epithelia samples (sigma.bccrc.ca) were retrieved from heavy current and former smokers. Publicly available Affymetrix CEL files were downloaded from NCBI Gene Expression Omnibus (GEO) (GSE3141, GSE10072 and GSE12428) 16, 17, 32, 47 or from The Sanger Cell Line Project at the BROAD Institute (Cambridge, MA, USA). Where appropriate, CEL files were grouped, and RMA analysis 48 was performed using the 'affy' package from Bioconductor (Bioconductor, Seattle, WA, USA). 49 Gene expression profiles for lung AC cell lines (n ¼ 38) were obtained by Human WG-6 gene expression chip. CN and gene expression data (EYA4 SAGE tag: TAATTTGTGT) from CIS specimens were obtained from a previous study (GSE7898).
19 EYA4 allelotypes data of 6q-linked familial lung cancers (n ¼ 194) and unrelated non-cancer controls (n ¼ 217) was obtained from a previous study. 50 Quantitative PCR validation was performed in triplicate using the primers: EYA4-Hs00187965_m1, 18s-Hs99999901_s1 and GADD45a-Hs00169255_m1. Protein lysates and western blots were prepared as described 51 (EYA4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), sc-15106; pTyr-H2AX (Millipore, Billerica, MA, USA), 07-1590; b-actin (Abcam, Cambridge, UK), ab8226). DNA sequencing was performed for EYA4 exons and proximal intronic sequences in 38 lung AC cell lines (listed in Supplementary Table S3) using previously described primers (Supplementary Table S8 ).
Statistical analyses
Correlation coefficients for EYA4 DNA methylation and mRNA expression levels for 38 lung AC cell lines were obtained by Spearman's tests, for each of the eight EYA4 DNA methylation probes against the average of the three EYA4 expression probes (Supplementary Table S3 ). For genomic integrity assessment, tumors were segregated into tertiles based on EYA4 expression and the proportion of genome altered was compared in tumors with low vs high EYA4 expression using a U-test. This analyses was applied to the 83 AC tumor pairs as well as publicly available matched CN and gene expression data from the Memorial Sloan Kettering Cancer Center, 14 for which matched CN (Agilent 44K arrays, Agilent, Santa Clara, CA, USA) and gene expression data (Affymetrix U133A arrays, Affymetrix) for 193 lung AC tumors were available. Memorial Sloan Kettering Cancer Center CN data was segmented using the segmentation algorithm, FACADE. 52 For survival analyses, data were downloaded from NCBI GEO 47 (GSE3141 and GSE12428). Highest and lowest tertiles of samples, based on EYA4 expression (probe 1561088_at), were analyzed using a log-rank (Mantel-Cox) test. Data from Liu et al. 50 were reanalyzed to determine whether EYA4 allelotypes were associated with risk in familial lung cancers. The statistical significance of the association between SNP allele and disease status was assessed primarily with CochranArmitage trend test with one degree of freedom, implemented in PLINK software. Allelic odds ratios associated with each SNP and 95% confidence intervals were estimated.
In vitro assays
Lung AC (NCI-H2122, NCI-H2405) and lymphoblastoid (NCI-HCC1954BL) cells were obtained from ATCC. Stable knockdowns of EYA4 were performed in triplicate for all cells using lentiviral vectors (clone i.d.: T TRCN0000051094), and a puromycin resistance selectable marker (Open Biosystems, Huntsville, AL, USA). Overexpression of EYA4 was performed in AC cells by transfection using Invitrogen's Ultimate ORF with clone i.d.: IOH57275. EYA4 was inserted by shuttle from entry vector pENTR221 to the lentiviral destination vector pLenti6.3/V5-DEST using LR recombination reaction. Lentiviral stock were produced using Invitrogen's ViraPower HiPerform Lentiviral expression system (Life Technologies, Carlsbad, CA, USA), after transfecting with lentiviral particles for 24 h and Blasticidin selection for 10-14 days. Soft agar colony formation was performed as described. 53 AV/PI staining for EYAkd and controls was performed (in triplicate), following 24 h serum starvation. Cells were washed in phosphate-buffered saline, resuspended in AV-binding buffer, PI and fluorescein isothiocyanate-conjugated anti-AV antibody (BD Bioscience, San Jose, CA, USA). Apoptotic cells were counted by flow cytometry in a FACS Canto II (BD Biosciences). gH2AX kinetics in response to radiation induced DNA damage was performed as described previously, 54 using 5 Gy radiation, and mouse monoclonal anti-phospho-Ser 13 H2AX primary antibody (Abcam; no. 18311, 1:4000 dilution; BD Bioscience Alexa Fluor 647-conjugated anti-gH2AX antibody, 4 0 ,6-diamidino-2-phenylindole). To account for differences in radiation-induced changes in cell cycle EYA4 is inactivated biallelically in sporadic lung cancer IM Wilson et al distribution that affect average gH2AX intensity measurements, gH2AX expression per cell was analyzed separately in G1-phase cells and results were expressed as a ratio of the signal intensity for irradiated vs unirradiated cells, and analyzed using the FACS Canto II flow cytometer. For cisplatin assays, 24 h after seeding, cells were treated for 72 h and then stained with Alamar Blue for absorbance analysis and IC50 calculation (GraphPad Prism 6 software, GraphPad, La Jolla, CA, USA).
Introduction
Lung cancer is the leading cause of cancer death worldwide. The 5-year survival rate is a mere 15% and there exists a lack of therapies to effectively treat this deadly disease. However, within the last decade, characterization of lung cancer genomes has revealed a number of genes critical to tumorigenesis, resulting in significant changes to lung cancer treatment and a subsequent increase in progression free and overall survival for a subset of these patients. These successes have prompted a search for additional driver alterations, and have identified a number of recurrently mutated genes including TP53, CDKN2A, PTEN, NRAS, BRAF, PIK3CA, DDR2, KEAP1, and NRF2 as well as gene fusions encompassing RET and ROS tyrosine kinases (1) (2) (3) (4) (5) .
In addition to somatic mutations, copy number alterations such as recurrent amplifications and deletions occur in almost all lung cancers (6, 7) . DNA amplification directly contributes to oncogene activation and the promotion of tumorigenesis, particularly for tumors driven by oncogene addiction. Oncogenes amplified at the DNA level therefore make ideal therapeutic targets as unlike loss of function tumor suppressor genes, they have the potential to be targeted directly. In nonsmall cell lung cancers (NSCLC), recurrent amplifications of several regions activate known oncogenes. These include: 1q21.2 (ARNT), 3q26.3-q27 (PIK3CA and SOX2), 5p15.33 (TERT), 7p11.2 (EGFR), 7q31.1(MET), 8p12 (FGFR1), 8q24.21 (MYC), 12q14.1 (CDK4), 14q13.3 (NKX2-1; refs. 7-13). Despite these discoveries, roughly 50% of lung cancers harbor no known targetable alterations, highlighting the need for a better understanding of the biology underlying lung tumorigenesis (2, 5) .
To identify novel oncogenes in NSCLC, we performed a large-scale integrative analysis of DNA copy number and gene expression on 261 lung tumors, spanning both major NSCLC subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SqCC). Our approach was based on the rationale that oncogenes selectively amplified and biologically relevant to NSCLC tumor biology would: (i) span regions of frequent high-level amplification, (ii) undergo frequent overexpression, and (iii) exert protumorigenic functions in vitro and in vivo. Our analysis identified a recurrent amplicon at 12q15, within which we identified the candidate oncogene YEATS domain containing 4, glioma-amplified sequence 41 (YEATS4/GAS41). In vivo and in vitro functional assays were performed to characterize the biologic effects and investigate the oncogenic mechanism of YEATS4 in lung tumorigenesis. Based on the frequency of YEATS4 amplification and overexpression in NSCLC tumors and cell lines, its role in viability, anchorage independent growth, senescence, and tumor formation, we propose that YEATS4 is novel candidate oncogene in lung cancer.
Materials and Methods
NSCLC tumor samples and cell lines
A total of 261 formalin-fixed paraffin-embedded and freshfrozen lung tumors (169 AC and 92 SqCC) were obtained under informed, written consent with approval from the University of British Columbia-BC Cancer Research and University of Toronto Ethics Board from patients undergoing surgical resection at the Vancouver General Hospital and the Princess Margaret Hospital, Toronto, Canada (14) . Tissue sections were microdissected with the guidance of lung pathologists and matched nonmalignant lung tissue obtained for a subset of the primary tumors. DNA was extracted using standard phenol-chloroform procedures. RNA was extracted from tumor and matched nonmalignant normal tissue using RNeasy Mini Kits (Qiagen) or TRIzol reagent (Invitrogen). Quality and quantity of genomic material was assessed using a NanoDrop 1000 spectrophotometer and by gel electrophoresis and/or by Agilent 2100 Bioanalyzer. Demographic information for this cohort is summarized elsewhere (14) . NSCLC cell lines H1993, H1355, H226, and A549 were obtained from American Type Culture Collection and HCC4011 from Dr. A. Gazdar and fingerprinted to confirm their identity (15) . All lines were cultured in RPMI-1640 medium supplemented with 10% FBS and 0.1% penicillin-streptomycin (Invitrogen). Immortalized normal human bronchial epithelial cells (HBEC) with (HBEC-KT53) and without p53 knockdown (HBEC-KT), courtesy of Dr. J. Minna, were cultured in K-SFM media supplemented with 50 ng/mL bovine pituitary extract and 5 ng/mL EGF (Invitrogen). Demographic data for the panel of cell lines used in this study can be found at http://edrn.jpl.nasa.gov/ ecas/data/dataset/urn:edrn:UTSW_MutationData.
Array comparative genomic hybridization and GISTIC analysis
Copy number profiles were generated for 261 NSCLC tumors using whole-genome tiling path array comparative genomic hybridization (aCGH), and were processed as previously described (16, 17) . Probes were mapped to the March 2006 (Hg18) genomic coordinates and aCGH-Smooth was used to segment and smooth log 2 ratio values (18) . The corresponding segments and ratio values were analyzed using the GISTIC algorithm (19) and gene pattern software (http://www.broadinstitute.org/ cancer/software/genepattern/) to identify regions of significant amplification across samples. Amplification threshold of 0.8, join segment size of 2, qv threshold 0.05, and removal of the X chromosome were the settings applied for analysis.
Gene expression profiling and data integration
Gene expression profiles were generated using custom Affymetrix microarrays for a subset (35 AC and 13SqCC) of the 261 tumors that had sufficient quantity and quality material for both tumor and matched nonmalignant tissue. Data were normalized using the Robust Multichip Average algorithm in R (20) . Genes were classified as over-or underexpressed if the mRNA fold change in tumors relative to matched nonmalignant was greater or less than 2-fold. Mann-Whitney U tests with Benjamini Hochberg correction P < 0.05 were used to compare expression of 12q15 genes between tumor and nonmalignant tissue in 83 AC pairs (EDRN) and determine whether increased gene dosage resulted in increased gene expression. A Spearman's correlation conducted using MATLAB software was used to determine the strength of the correlation between copy number and expression, with a coefficient >0.55 considered significant.
In vitro and in vivo assays were performed as previously described (21) (22) (23) (24) (25) . Detailed information can be found in the supplemental methods.
Results
Recurrently amplified regions in NSCLC
Copy number profiles for 169 AC and 92 SqCC were generated using aCGH. Significant regions of high-level amplification (log 2 ratio >0.8) were identified using the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm, which calculates significance scores by considering both the amplitude and frequency of copy number alterations (19) . GISTIC analysis of all 261 samples (NSCLC) identified 3 significant regions of focal amplification: 7p11. Fig. 1A-C) . Amplification of these regions has been previously described in NSCLC, indicating our tumors display patterns of alteration characteristic of lung cancer (2, 7, 26, 27) .
Although none of the regions identified were common between all 3 analyses, all of the regions identified in NSCLC were also significant in a subtype-specific manner. Further examination of these amplicons revealed that known oncogenes EGFR and BRF2, both of which are known to be preferentially amplified in SqCC (21, 28) , were driving selection of the 7p11.2 and 8q12 amplicons, respectively. Intriguingly, the primary target of 12q15 amplification, which is believed to be MDM2-a ubiquitin ligase that targets TP53 for proteasomal degradation, and when overexpressed results in aberrant p53 inactivation, was excluded from both the focal and wide peak boundaries. The exclusion of MDM2 from this focal region suggested that a gene other than MDM2 may be driving selection of this amplicon. This combined with the fact that all other regions harbored known oncogenes 7p11.2 (EGFR), 8p11.23 (FGFR1), 8p12 (BRF2), 14q13.3 (NKX2-1), 20q13.3 (EEF1A), or are known to be subtype-specific regions of amplification (1p34.2 and 3q in SqCC; refs. 2, 7) prompted us to further explore the 12q15 amplicon.
Identification of YEATS4, the target of 12q15 amplification
The peak amplified region of 12q15 spanned a 432 kb interval (68,030,736-68,462,888) and contained 7 genes; LYZ, YEATS4, FRS2, CCT2, LRRC10, BEST3, and RAB3IP, none of which have been previously implicated in lung tumorigenesis ( Fig. 1;  Supplementary Table S1 ). Based on the notion that selectively amplified oncogenes would demonstrate elevated expression, we integrated copy number and gene expression data for adenocarcinoma tumors and matched nonmalignant tissue. Because of the limited size of our dataset with both copy number and expression data, identification of the 12q15 driver gene was performed in the largest dataset available (EDRN, n ¼ 83). Of the 7 genes within the amplicon, only YEATS4 was both gained/amplified and concomitantly overexpressed in lung tumors relative to matched nonmalignant tissues ( Fig. 2A-C) . Although YEATS4 has not been previously described in lung cancer, it is a well-established oncogene in cancers of neural origin (29, 30) and frequently amplified in liposarcomas (31).
YEATS4 is frequently amplified and overexpressed in NSCLC
YEATS4 was amplified in 18% (47/261) and overexpressed in 31% (15/48) of cases from our cohort. Although 12q15 was not significant in the GISTIC analysis of our 92 SqCC cases, to conclusively determine whether amplification of YEATS4 was specific to AC, we compared copy number and expression data for both subtypes. Although no statistical difference in YEATS4 copy number or expression was observed between subtypes ( Supplementary Fig. S1B-S1D ), on average AC tumors had a higher number of copies and greater fold change in expression compared with SqCC tumors. This suggests that although copy gain is a frequent event in both subtypes, it is likely a broader amplification event that occurs at a lower amplitude in SqCC relative to AC, which is why 12q15 failed to be identified by GISTIC in the SqCC tumors. Analysis of external datasets with both AC and SqCC data supported our findings, with gain/ amplification and overexpression occurring at similar frequencies in both datasets ( Table 1 ), indicating that amplification and overexpression of YEATS4 is not subtype specific.
To gain further insight into the prevalence of YEATS4 amplification, we investigated YEATS4 copy number and expression in publicly available NSCLC tumor datasets. YEATS4 was gained (2.3-5 copies) or amplified (>5 copies) at various frequencies across the 5 datasets, ranging from 5% to 22% and 0.4% to 5%, respectively (Table 1) . A broader analysis of 508 human cancer cell lines revealed YEATS4 copy gain/amp in 43/128 (33.6%) of lung cancer cell lines and in 117/508 (23%) of all cancer cell lines (Table 1) . Expression analysis of the EDRN and TCGA datasets revealed YEATS4 was overexpressed at comparable frequencies to our dataset; 18% (15/83) and 33% (14/42), respectively (Table 1) . Taken together, these results show YEATS4 is frequently gained and overexpressed in NSCLC, irrespective of subtype, as well as gained in many other human cancers. Fig. 2D; Supplementary Fig.   S1A ). Moreover, analysis of the 35 AC samples with expression data revealed a strong correlation between array findings and PCR results (r ¼ 0.75, P < 0.001, Pearson correlation, data not shown), validating array findings and confirming frequent overexpression of YEATS4. Western blotting of cell lines with and without YEATS4 amplification revealed increased YEATS4 expression in lines with amplification, demonstrating that amplification drives overexpression at both the mRNA and protein level (Fig. 2E) . 
Association of YEATS4 and clinical features
Multivariate analysis of YEATS4 copy number and expression revealed no significant associations between any clinical features (age, sex, stage, smoking status, race). Survival analysis of the Director's challenge expression datasets (32) using a Cox-regression analysis revealed a trend toward poorer survival in patients with YEATS4 amplification, however this association failed to reach statistical significance in any of the datasets examined (data not shown).
YEATS4 displays oncogenic properties in vitro and in vivo YEATS4 encodes a protein found in a number of multisubunit protein complexes involved in chromatin modification and transcriptional regulation and has also been shown to be involved in the regulation of TP53. To assess its oncogenic potential, YEATS4 was stably transfected into 2 immortalized HBEC lines; HBEC-KT and HBEC-KT53 (KT-YEATS and KT53-YEATS). Empty vector transfected cells were used as controls (KT-EV and KT53-EV). YEATS4 gene and protein expression was confirmed by qPCR and Western blot ( Fig.  3A and B) . Relative to controls, ectopic expression of YEATS4 had no effect on viability and failed to induce anchorage-independent growth in HBECs (data not shown), indicating that in immortalized normal cells YEATS4 overexpression alone is incapable of inducing colony formation. However, a dramatic inhibition of senescence in overexpressing cells relative to controls was observed in both lines (Student t test, P < 0.05; Fig. 3C and D) , suggesting elevated YEATS4 expression is capable of inducing a phenotype associated with malignant transformation.
Complimentary knockdown experiments using lentiviral shRNAs were performed in lung cancer cell lines with (H1993, H1355, H226) and without (A549, HCC4011) YEATS4 amplification and various TP53 backgrounds (Supplementary Table  S2 ). Empty vector transfected cells were used as controls (PLKO) and knockdown was confirmed by qPCR and Western blotting ( Fig. 4A and B) . Knockdown significantly decreased cell viability in H1993 and H1355 (P ¼ 0.0127 and 0.0172, respectively), both of which harbor YEATS4 amplification and mutant p53 (Fig. 4C) , but had no effect on A549, HCC4011, or H266 lines (P ¼ 0.428, 0.45, and 0.49, respectively) which do not harbor YEATS4 amplification (A549 &H4011), or have YEATS4 amplification with wild-type (wt) p53 (H226; Fig. 4C ). Similarly, knockdown resulted in a significant decrease in anchorage-independent colony formation in H1993 (P ¼ 7.26 Â 10 À6 ) and H1355 (P ¼ 6.06 Â 10
À10
) cells, but not in A549 (P ¼ 0.97), H4011 (P ¼ 0.21), or H226 (P ¼ 0.74) cells, indicating wt p53 may abrogate the effect of YEATS4 knockdown on viability and colony formation in lines with amplification (Fig. 4D) . A significant increase in senescence was observed in all 3 lines with amplification; H1993 (P ¼ 5.71 Â 10 À6 ), H1355 (P ¼ 0.0012), and H226 (P ¼ 1.21 Â 10
À13
) as well as moderate increase in A549 (P ¼ 2.99 Â 10 À7 ). No difference in senescence was observed in HCC4011 (P ¼ 0.06; ref. Fig. 4E ). The finding that A549 cells showed a modest increase in senescence is not surprising given the role of YEATS4 in the p53 pathway (discussed below) and the wt p53 background of Table 1 . this line, which enables pathway activation and cellular senescence.
To explore the oncogenic potential of YEATS4 in vivo, tumor formation in NOD/SCID mice was examined by subcutaneous flank injections of H1993 and H1355 control and shY4 cells. Tumor formation was significantly reduced in shY4 cells of both cell lines at all time points (Fig. 4F and G ). Our results demonstrate that knockdown of YEATS4 in cell lines with amplification effectively inhibits tumorigenesis, with a significant inhibition in viability, tumor and anchorage-independent growth, and increased cellular senescence, strongly supporting YEATS4 as an oncogene in NSCLC.
YEATS4 suppresses p53 and p21
Inactivation of the p53 pathway is one of the most frequent alterations in lung cancer, with somatic mutations occurring in approximately 50% of all cases (28, 33) . p53 is a key tumor suppressor that regulates cell cycle, DNA repair, apoptosis, and senescence and inhibits aberrant proliferation and the propagation of damaged cells. A study by Park and colleagues showed that under normal, unstressed conditions, YEATS4 binds to and inhibits the promoters of p14 and p21, subsequently repressing the p53 tumor suppressor pathway (34) . To assess whether this interaction occurs in NSCLC, we assessed these proteins in cell lines with YEATS4 manipulation. Upon YEATS4 knockdown, p21 and p53 protein levels were increased, with the greatest increases in expression of p21 and p53 observed in cell lines harboring YEATS4 amplification or wt p53, respectively (Fig. 5A) . No change in p14 levels was observed upon knockdown. Overexpressing lines showed a modest reduction of p21 and p14 as well as a reduction of p53 levels in HBEC-KT (Fig. 5B) . MDM2 levels remained unchanged following knockdown or overexpression of YEATS4, indicating that the observed changes in p21, p14, and p53 were a direct result of YEATS4 manipulation.
YEATS4 alters the sensitivity of cell lines to cisplatin and nutlin
To determine whether the downstream effects of YEATS4 manipulation alters cellular sensitivity to chemotherapy, cell lines were treated with serial dilutions of cisplatin, a commonly prescribed first line chemotherapy for lung cancer patients that crosslinks DNA triggering apoptosis, or nutlin, a cisimidazoline analog that inhibits the interaction of p53 and MDM2, stabilizing p53. Based on the observed effects on p53 and p21 protein levels following manipulation of YEATS4 expression and the notion that cells with YEATS4 amplification may be dependent on YEATS4 for growth and survival, we hypothesized that HBEC-KT/KT53-Y cells would be more resistant to treatment, whereas shY4 cells harboring YEATS4 amplification would be more sensitive. As expected, HBEC-KT-YEATS and HBEC-KT53-YEATS lines were significantly more resistant to both cisplatin and nutlin than their control counterparts ( Fig. 5C ; Table 2 ). Differences in sensitivity were less consistent in the lung cancer cell lines, likely because of the fact these cell lines harbor numerous genomic alterations that could influence drug sensitivities. Although H1993 shY4 cells were significantly more sensitive to cisplatin (IC 50 PLKO:11.45 vs. shY4:8.65; Fig.  5D ) supporting our hypothesis, knockdown in both H1355 and H226, showed the opposite trend resulting in greater resistance relative to controls ( Table 2) . As anticipated, A549 and HCC4011 shY4 cells showed no difference in sensitivity ( Table  2) . As specimens with mutant p53 are resistant to nutlin, only A549 and H226 were treated. Similar to the cisplatin results, A549 shY4 cells showed no significant difference in sensitivity to nutlin (PLKO: 7.58 vs. shY4:6.91; P ¼ 0.84), whereas H226 shY4 cells were unexpectedly significantly more resistant (PLKO:3.27, shY4:4.33, P ¼ 0.033; Table 2 ). Analysis of lung cancer cell line IC 50 data from the Sanger drug sensitivity project failed to reveal a significant association between YEATS4 amplification and response to cisplatin or nutlin. However, based on the fact that transformed bronchial epithelial cells, which harbor minimal genetic alterations, were significantly more resistant to cisplatin and nutlin following overexpression of YEATS4, and H1993 shY4 cells (which harbor the greatest amplification of YEATS4) were more sensitive to cisplatin compared with controls, we feel this data supports the notion that YEATS4 alters the in vitro sensitivity of lung cells to cisplatin and nutlin.
Sensitivity to cisplatin is not mediated solely through the p53-p21 pathway
To gain further insight into the potential mechanisms of altered sensitivity to cisplatin, we treated cell lines with 40mmol/L cisplatin for 48 hours, and collected protein lysates at 0, 24, and 48 hours posttreatment. As expected, cisplatin treatment of HBECs resulted in an increase in p53, p53 Ser15 phosphorylation (a marker of stabilization), p21, and induced apoptosis as measured by cleaved PARP. However, no differences between HBEC-EV and HBEC-YEATS cells were observed for any of the proteins examined ( Supplementary Fig. S2 ). In shY4 cells with amplification, treatment with cisplatin led to a greater induction of p53 and phospho-p53 (Ser15), and in H226 also led to a significant increase in p21 levels relative to control cells (Fig. 5E) . As no significant differences in protein levels between HBEC-EV and HBEC-YEATS were observed, despite a significant increase in resistance following overexpression, our results suggest that although the p53-p21 signaling pathway may be involved, resistance is likely mediated through the interaction of YEATS4 with other signaling pathways.
YEATS4 knockdown phenotypes are independent of p21 signaling in mutant p53 cells
To explore the effect of increased p21 expression on the observed phenotypes following knockdown, siRNA knockdown of CDKN1A was performed on shY4 and PLKO cells for cell lines with YEATS4 amplification (H1993, H1355, and H226). Knockdown of CDKN1A showed no effect on viability or colony formation in any of the lines (data not shown), but significantly altered senescence levels in the presence of wt p53 (Supplementary Fig. S2A ). CDKN1A siRNA reduced senescence in both H226 shY4 and PLKO cells relative to nontargeting control siRNA-treated cells, such that the percent of senescent H226 shY4-p21 cells was similar to H226 PLKO-NTC (Supplementary Fig. S2B ). The findings from these experiments suggest that in a wild-type p53 background, the increase in senescence following YEATS4 knockdown occurs in a p53-dependent manner and is the direct result of increased p21-expression. As CDKN1A knockdown failed to rescue viability, colony formation, and senescence in cell lines with mutant p53, these findings further support the notion that the phenotypes observed following knockdown of YEATS4 are not solely because of changes in p53-p21 signaling. Based on these findings, and the prominent role of Rb in senescence, we investigated whether the increased senescence following YEATS knockdown could be because of altered Rb signaling. We observed modest reductions in Rb Ser807/811 phosphorylation following YEATS knockdown, which in mutant p53 cell lines seems to be due in part to reduced levels of p27 ( Supplementary Fig. S2C ).
Identification of additional cellular networks regulated by YEATS4
In an attempt to gain a better understanding of other pathways YEATS4 is involved in, we performed expression profiling on shY4 and PLKO cells for the 3 cell lines with YEATS4 amplification. To identify significantly enriched pathways/networks and gene sets affected by YEATS4 knockdown, Ingenuity Pathway Analysis and Gene Set Enrichment Analysis (GSEA) were performed. A total of 32 genes (27 overexpressed and 5 underexpressed) were differentially expressed between knockdown and control cells across all 3 cell lines. Because of the small number of input genes, none of the significantly enriched canonical pathways passed multiple testing correction. However, network analysis, which assesses regulatory relationships existing between genes and proteins, identified 2 networks associated with protumorigenic functions: (1) cancer and (2) cell death, survival, cell cycle, and cell morphology. These networks were centered around known targets or binding partners of YEATS4 including p53, CDKN1A, and MYC ( Supplementary  Fig. S3 ), further supporting our in vitro findings. Preranked GSEA revealed significant enrichment of a number of transcription factor gene sets including MYCN, which has been shown to be a binding partner of YEATS4 and all 6 serum response factor (SRF) gene sets. SRF is a ubiquitously expressed transcription factor implicated in cell proliferation, differentiation, metastasis, and clinically associated with castration-resistant prostate cancer (35, 36) . Interestingly, PDLIM7, which contains a serum response element and is transcribed upon induction of SRF, was shown to inhibit p53 and p21 through the inhibition of MDM2 selfubiquitination. Although neither MYCN, SRF, or PDLIM7 were differentially disrupted at the mRNA level following knockdown, our downstream analysis suggests the target genes of these 2 transcription factors could be involved in YEATS4-mediated tumorigenesis and warrant investigation in future studies to elucidate additional mechanisms through which YEATS4 promotes tumorigenesis.
Discussion
Although single-dimensional genomic analyses have been instrumental in cancer gene discovery, this type of analysis often overlooks genes disrupted at low frequencies, and is unlikely to distinguish causal from passenger events. The integration of multiple parallel genomic dimensions enables the identification of genes with concurrent DNA and expression alterations, which are likely selected for because of their roles in driving cancer phenotypes (37) . Toward this end, we integrated copy number and gene expression data in an attempt to identify novel oncogenes important in lung tumorigenesis. Although our analysis revealed gains/amplifications in a number of regions previously reported in NSCLC, the amplicon at 12q15 was the only one without a candidate driver gene located within the amplicon boundaries and was therefore the only regions we pursued further. Integration of expression and copy number data for the 7 genes located within 12q15 identified YEATS4 as the candidate target gene of this amplicon.
First identified and isolated in the glioblastoma multiforme cell line TX3868, YEATS4 is a highly conserved nuclear protein essential for cell viability that is frequently amplified in gliomas, astrocytomas, and liposarcomas (29, 31, 38) . A member of a protein family characterized by the presence of an N-terminal YEATS domain, YEATS4 shares high homology with transcription factor family members AF-9 and ENL (39). Like other family members, YEATS4 is involved in chromatin modification and transcriptional regulation through its incorporation into multisubunit complexes; specifically the human TIP60/TRRAP and SRCAP complexes (40, 41) , which mediate the incorporation of an H2A variant histone protein into nucleosomes, altering chromatin structure and controlling transcriptional regulation.
In addition to its role in transcriptional regulation, yeast 2 hybrid screens have revealed a number of YEATS4 binding partners. These include MYC, MYCN, TACC1, TACC2, NuMa, AF10, PFDN1, and KIAA1009 (42) (43) (44) (45) (46) . Analysis of expression data before and after YEATS4 knockdown showed no effect on expression of any binding partners, suggesting that YEATS4 does not control the expression of its binding partners at the mRNA level. To date, the majority of work surrounding YEATS4 has focused primarily on the identification of YEATS4 binding partners with only a few studies having explored the phenotypic effects of YEATS4 amplification, none of which have been performed in lung (34, 46) .
Our study is the first to show gain/amplification and overexpression of YEATS4 in NSCLC and the first to implicate amplification of YEATS4 in lung cancer tumorigenesis. We observed frequent gain/amplification of YEATS4 in multiple independent tumor cohorts in addition to our own, as well as a strong correlation between gain and overexpression in both tumors and cell lines (Fig. 2) . Analysis of the catalogue of somatic mutations in cancer (COSMIC) revealed YEATS4 is rarely mutated in lung (0.23%) or any cancer type (0.17%), suggesting that DNA amplification is the predominant Cancer Researchmechanism of activation. In addition to the genomic evidence supporting selection of YEATS4 in NSCLC, we demonstrate the oncogenic potential of YEATS4 both in vitro and in vivo (Figs. 3  and 4) . Ectopic expression resulted in a significant reduction in senescence, suggesting overexpression of YEATS4 is sufficient to induce phenotypic changes characteristic of malignant transformation (Fig. 3) , whereas knockdown in cell lines with amplification and mutant p53 showed reduced viability and colony formation along with an increase in senescence, consistent with oncogenic function. Although wt p53 abrogates the effects on viability and colony formation on YEATS4 knockdown lines with amplification, a significant increase in senescence was still observed. In addition to these phenotypic effects, we also demonstrated that YEATS4 inhibits p21 thereby repressing p53 activity, consistent with the findings of Park and Roeder who demonstrated this interaction in unstressed conditions (34) . siRNA-mediated knockdown of CDKN1A failed to rescue viability, colony formation, and senescence in mutant p53 backgrounds, suggesting the phenotypic effects of YEATS4 amplification occur through a mechanism other than p21. MDM2, an E3 ubiquitin ligase, is the major negative regulator of p53, mediating its ubiquitination and subsequent degradation (47, 48) . Overexpression results in inactivation of p53 and is a common mechanism of p53 inactivation in cancer. MDM2 is frequently amplified and overexpressed in human cancers including lung cancer, and is largely considered to be the driver gene of the 12q15 amplicon (7, 49) . We were therefore intrigued to discover that despite being frequently gained in our dataset, MDM2 did not fall within the boundaries of the 12q15 amplicon identified in our cohort. This led us to suppose that an alternative oncogene was being selected for in this region. When looking at high-resolution copy number profiles, although the majority of cases showed identical copy number for both YEATS4 and MDM2, a small number of cases (3/83) had more copies of YEATS4 than MDM2, suggesting YEATS4 is selected as the target of amplification in these samples and that amplification of YEATS4 is not merely a passenger event of MDM2 amplification. Of note, 4 of 83 cases had higher level gain/amplification of MDM2 relative to YEATS4. For cancers with amplification of 12q15 spanning both YEATS4 and MDM2, these genes may work synergistically to suppress p53, however further experimentation is required to investigate this hypothesis. Along with the many tumor promoting effects of YEATS4, of immediate clinical interest is our discovery of a YEATS4 dependent mechanism of reduced cisplatin and nutlin sensitivity, which seems to occur at least in part through inhibition of p21 and subsequent suppression of the p53 pathway.
In summary, we have shown YEATS4 is frequently amplified and overexpressed in NSCLC and together with its multiple oncogenic functions suggests it is a novel oncogene in lung cancer. Given the effect of YEATS4 on the p53 pathway, we propose that MDM2 is not the sole driver gene targeted by amplification of 12q15 and that suppression of the p53 pathway can be achieved through amplification of YEATS4. Additional investigation into the signaling pathways altered as a result of YEATS4 amplification will provide further insight into the mechanism underlying YEATS4-mediated tumorigenesis.
